Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Apple Turns 50: From Garage Startup to AI Crossroads 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Britain Courts Anthropic Amid US Defense Department Dispute 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
IRVINE, Calif., July 31, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq:OCUL). Investors who purchased or otherwise acquired shares between May 5, 2017 and July 6, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the September 5, 2017 lead plaintiff motion deadline.
If you purchased Ocular shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, during the Class Period, Ocular made false and/or misleading statements and/or failed to disclose: that the Company’s management misled investors about DEXTENZA manufacturing issues, including that more than half of lots manufactured by Ocular contain bad product; that such manufacturing issues could endanger the approval of DEXTENZA by the Food and Drug Administration; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this news reached the public, shares of Ocular declined in value materially, which caused investors harm according to the Complaint.
If you want to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
